Quick Answer
Marker Therapeutics, Inc. reported Net Income Loss of -$12.16 million for the year ending 2025.
- Marker Therapeutics, Inc. showed a decrease of -13.3% in Net Income Loss from 2024 to 2025.
- This data is from Marker Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on March 18, 2026.
- XBRL data for this metric is available from 2000 to 2025 (26 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2010: -$1.34 million | Q1 2011: -$1.27 million | Q2 2011: -$404.4 thousand | Q1 2012: -$598.6 thousand | Q1 2013: -$1.08 million | Q2 2013: -$870.8 thousand | Q1 2014: -$29.71 million | Q2 2014: $753.5 thousand | Q3 2014: -$1.57 million | Q1 2015: -$700.7 thousand | Q2 2015: -$60.22 million | Q3 2015: $28.50 million | Q1 2016: -$4.75 million | Q2 2016: $5.97 million | Q3 2016: -$2.10 million | Q1 2017: -$2.42 million | Q2 2017: -$1.89 million | Q3 2017: -$3.99 million | Q1 2018: -$3.20 million | Q2 2018: -$4.81 million | Q3 2018: -$4.39 million | Q1 2019: -$5.32 million | Q2 2019: -$5.57 million | Q3 2019: -$5.46 million | Q1 2020: -$6.49 million | Q2 2020: -$6.34 million | Q3 2020: -$7.37 million | Q1 2021: -$8.78 million | Q2 2021: -$10.91 million | Q3 2021: -$12.43 million | Q1 2022: -$9.91 million | Q2 2022: -$9.24 million | Q3 2022: -$6.92 million | Q1 2023: -$4.97 million | Q2 2023: $2.52 million | Q3 2023: -$2.98 million | Q1 2024: -$2.39 million | Q2 2024: -$2.19 million | Q3 2024: -$2.31 million | Q1 2025: -$4.45 million | Q2 2025: -$4.02 million | Q3 2025: -$2.00 million.
- Over the full 26 years of available data (2000 to 2025), Marker Therapeutics, Inc.'s Net Income Loss has declined by 1,200.5%.
- Historical annual values: Fiscal year 2025: -$12.16 million | Fiscal year 2024: -$10.73 million | Fiscal year 2023: -$8.24 million | Fiscal year 2022: -$29.93 million | Fiscal year 2021: -$41.88 million | Fiscal year 2020: -$28.71 million | Fiscal year 2019: -$21.43 million | Fiscal year 2018: -$147.96 million | Fiscal year 2017: -$10.98 million | Fiscal year 2016: -$2.46 million | Fiscal year 2015: -$34.07 million | Fiscal year 2014: -$30.88 million | Fiscal year 2013: -$5.53 million | Fiscal year 2012: -$5.86 million | Fiscal year 2011: -$2.03 million | Fiscal year 2010: -$3.53 million | Fiscal year 2009: -$17.35 million | Fiscal year 2008: -$2.20 million | Fiscal year 2007: -$3.89 million | Fiscal year 2006: -$1.30 million | Fiscal year 2005: -$985.6 thousand | Fiscal year 2004: -$2.68 million | Fiscal year 2003: -$5.78 million | Fiscal year 2002: -$2.28 million | Fiscal year 2001: -$672.0 thousand | Fiscal year 2000: -$935.3 thousand.
- Data sourced from SEC EDGAR public filings as of August 6, 2026.
Last verified: